Immunology and immunotherapy in breast cancer

作     者：Vladimir Semiglazov Andrey Tseluiko Asel Kudaybergenova Anna Artemyeva Petr Krivorotko Roman Donskih Vladimir Semiglazov;Andrey Tseluiko;Asel Kudaybergenova;Anna Artemyeva;Petr Krivorotko;Roman Donskih

作者机构：Petrov National Medicine Cancer-Research Center Ministry of HealthSaint-Petersburg 197758Russia 

出 版 物：《Cancer Biology & Medicine》 (癌症生物学与医学（英文版）)

年 卷 期：2022年第19卷第5期

页      面：609-618页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Breast cancer tumor-infiltrating lymphocytes PD-1 PD-L1 immunotherapy 

摘      要：Immuno-oncology is a rapidly developing field in *** combination therapies have already been studied in many clinical trials on various tumor *** recent years,a checkpoint inhibition therapy with monoclonal antibodies targeting PD-1 and its ligand PD-L1 has been *** cancer had been examined in the field of immune-oncology relatively *** review focuses on clinical evidence regarding immune checkpoint inhibition for curative treatment of various breast cancer *** addition,we present the results of studies demonstrating the prognostic and predictive value of levels of tumorinfiltrating lymphocytes(CD4 and CD8),their quantitative ratios,and their correlation with regulatory genes(PD-1,PD-L1,and FOX-P3).